MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Compugen Ltd

Slēgts

1.47 2.8

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.4

Max

1.47

Galvenie mērījumi

By Trading Economics

Ienākumi

-7.4M

-6.1M

Pārdošana

-16M

1.5M

P/E

Sektora vidējais

60.333

57.333

EPS

-0.07

Peļņas marža

-415.84

Darbinieki

74

EBITDA

-12M

-7.5M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+177.78% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 19. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-624M

136M

Iepriekšējā atvēršanas cena

-1.33

Iepriekšējā slēgšanas cena

1.47

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Compugen Ltd Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. apr. 23:54 UTC

Karstas akcijas

Stocks to Watch: Alphabet, Intel, AppFolio

2025. g. 24. apr. 23:51 UTC

Tirgus saruna

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

2025. g. 24. apr. 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 24. apr. 23:46 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

2025. g. 24. apr. 23:37 UTC

Top Ziņas

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

2025. g. 24. apr. 23:36 UTC

Top Ziņas

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

2025. g. 24. apr. 23:13 UTC

Top Ziņas
Peļņas

Google's Earnings Power Holds Up in Global Turbulence -- Update

2025. g. 24. apr. 23:09 UTC

Top Ziņas

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

2025. g. 24. apr. 23:02 UTC

Iegādes, apvienošanās, pārņemšana

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

2025. g. 24. apr. 23:02 UTC

Iegādes, apvienošanās, pārņemšana

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

2025. g. 24. apr. 22:51 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

2025. g. 24. apr. 22:48 UTC

Top Ziņas

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

2025. g. 24. apr. 22:47 UTC

Tirgus saruna

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

2025. g. 24. apr. 22:38 UTC

Tirgus saruna
Peļņas

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

2025. g. 24. apr. 22:24 UTC

Peļņas

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

2025. g. 24. apr. 22:24 UTC

Peļņas

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

2025. g. 24. apr. 22:24 UTC

Tirgus saruna
Peļņas

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

2025. g. 24. apr. 22:23 UTC

Peļņas

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

2025. g. 24. apr. 22:11 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 24. apr. 22:11 UTC

Tirgus saruna
Peļņas

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

2025. g. 24. apr. 22:09 UTC

Top Ziņas
Peļņas

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

2025. g. 24. apr. 22:00 UTC

Tirgus saruna
Peļņas

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

2025. g. 24. apr. 21:39 UTC

Top Ziņas

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

2025. g. 24. apr. 21:24 UTC

Top Ziņas
Peļņas

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

2025. g. 24. apr. 21:24 UTC

Top Ziņas
Peļņas

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

2025. g. 24. apr. 21:23 UTC

Top Ziņas
Peļņas

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

2025. g. 24. apr. 21:04 UTC

Peļņas

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

2025. g. 24. apr. 21:03 UTC

Peļņas

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

2025. g. 24. apr. 21:03 UTC

Peļņas

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

2025. g. 24. apr. 21:02 UTC

Peļņas

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Salīdzinājums

Cenas izmaiņa

Compugen Ltd Prognoze

Cenas mērķis

By TipRanks

177.78% augšup

Prognoze 12 mēnešiem

Vidējais 4 USD  177.78%

Augstākais 4 USD

Zemākais 4 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Compugen Ltd — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

3

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

1.38 / 1.5Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Very Strong Bearish Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.